Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3.2/5
Hugel Inc (145020 KS)
Watchlist
53
Analysis
Health Care
•
South Korea
Hugel, Inc. is a Bio-pharmaceutical company that focuses on developing beauty/cosmetics related products. The Company's main products include botulinum toxin and fillers.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
22 Jun 2025 00:30
APAC Healthcare Weekly (June 22)- Samsung Biologics, Daewoong Pharma, Shionogi, Simcere, CSL
Samsung Bio launches new service for early-stage biotechs. Shionogi’s tender offer for Torii becomes successful. Simcere stuck outlicensing deal....
Tina Banerjee
Follow
425 Views
Share
bullish
•
Thematic (Sector/Industry)
•
25 May 2025 00:30
APAC Healthcare Weekly (May 25)- 3SBio, Samsung Biologics, Celltrion, CSPC Pharma, Chugai
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
Tina Banerjee
Follow
580 Views
Share
bullish
•
Thematic (Sector/Industry)
•
04 May 2025 00:30
APAC Healthcare Weekly (May 4)- Takeda Pharma, Samsung Biologics, Celltrion, Dr. Reddy’s, Medanta
Takeda retained top slot in domestic market. Samsung Biologics signed major CDMO deal with US client. Celltrion got approval to start trial of...
Tina Banerjee
Follow
615 Views
Share
bullish
•
SK Innovation
•
09 Mar 2025 08:04
Got the BBIG Rebalancing Results: SK Innovation Is the Trade This Week
This post provides insights into the latest BBIG rebalancing results, breaking down the key shifts and highlighting SK Innovation as the top trade...
Sanghyun Park
Follow
641 Views
Share
bullish
•
Thematic (Sector/Industry)
•
09 Feb 2025 00:30
APAC Healthcare Weekly (Feb 9)- Daiichi Sankyo, Astellas, SanBio, IHH, Henlius Biotech, Dr. Reddy’s
APAC healthcare companies continued to get approvals for new products and initiates clinical trials. The companies continued with acquisitions and...
Tina Banerjee
Follow
774 Views
Share
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.55.0
x